Staff Profile
Dr Helen Blair
Research Associate
- Telephone: +44 (0)191 208 2240
- Address: Dr Helen J Blair
Translation and Clinical Research Institute,
Faculty of Medical Sciences,
Newcastle University,
Wolfson Childhood Cancer Research Centre,
Herschel Building, Level 6,
Brewery Lane,
Newcastle upon Tyne,
NE1 7RU, UK.
Publications
-
Articles
- Coleman DJL, Keane P, Chin PS, Ames L, Kellaway S, Blair H, Khan N, Griffin J, Holmes E, Maytum A, Potluri S, Strate L, Koscielniak K, Raghavan M, Bushweller J, Heidenreich O, Rabbitts T, Cockerill PN, Bonifer C. Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1. iScience 2024, 27(4), 109576.
- Tirtakusuma R, Milne P, Blair HJ, Shi Y, Bomken S, Heidenreich O. Fusion transcripts are present in early progenitor cells in KMT2A-rearranged B-ALL. Leukemia 2024, 38, 883-886.
- Bell HL, Blair HJ, Jepson Gosling SJ, Galler M, Astley D, Moorman AV, Heidenreich O, Veal GJ, van Delft FW, Lunec J, Irving JAE. Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. Leukemia 2024, 38, 1223-1235.
- Rasouli M, Blair H, Troester S, Szoltysek K, Cameron R, Ashtiani M, Krippner-Heidenreich A, Grebien F, McGeehan G, Zwaan CM, Heidenreich O. The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML. HemaSphere 2023, 7(8), e935.
- Bell HL, Blair HJ, Singh M, Moorman AV, Heidenreich O, van Delft FW, Lunec J, Irving JAE. Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. Cancer Cell International 2023, 23, 202.
- Sinclair PB, Cranston RE, Raninga P, Cheng J, Hanna R, Hawking Z, Hair S, Ryan SL, Enshaei A, Nakjang S, Rand V, Blair HJ, Moorman AV, Heidenreich O, Harrison CJ. Disruption to the FOXO-PRDM1 axis resulting from deletions of chromosome 6 in acute lymphoblastic leukaemia. Leukemia 2023, 37, 636–649.
- Stolzel F, Fordham SE, Nandana D, Lin W-Y, Blair H, Elstob C, Bell HL, Mohr B, Ruhnke L, Kunadt D, Dill C, Allsop D, Piddock R, Soura E-N, Park C, Fadly M, Rahman T, Alharbi A, Wobus M, Altmann H, Rollig C, Wagenfuhr L, Jones GL, Menne T, Jackson GH, Marr HJ, Fitzgibbon J, Onel K, Meggendorfer M, Robinson A, Bziuk Z, Bowes E, Heidenreich O, Haferlach T, Villar S, Ariceta B, Diaz RA, Altschuler SJ, Wu LF, Prosper F, Montesinos P, Martinez-Lopez J, Bornhauser M, Allan JM. Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia. JCI Insight 2023, 8(2), e150368.
- Pringle TA, Chan CD, Luli S, Blair HJ, Rankin KS, Knight JC. Synthesis and In Vivo Evaluation of a Site-specifically Labeled Radioimmunoconjugate for Dual-Modal (PET/NIRF) Imaging of MT1-MMP in Sarcomas. Bioconjugate Chemistry 2022, 33(8), 1564-1573.
- Pal D, Blair H, Parker J, Hockney S, Beckett M, Singh M, Tirtakusuma R, Nelson R, McNeill H, Angel SH, Wilson A, Nizami S, Nakjang S, Zhou P, Schwab C, Sinclair P, Russell LJ, Coxhead J, Halsey C, Allan JM, Harrison CJ, Moorman AV, Heidenreich O, Vormoor J. hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia. Cell Reports Medicine 2022, 3(8), 100717.
- Tirtakusuma R, Szoltysek K, Milne P, Grinev VV, Ptasinska A, Chin PS, Meyer C, Nakjang S, Hehir-Kwa JY, Williamson D, Cauchy P, Keane P, Assi SA, Ashtiani M, Kellaway SG, Imperato MR, Vogiatzi F, Schweighart EK, Lin S, Wunderlich M, Stutterheim J, Komkov A, Zerkalenkova E, Evans P, McNeill H, Elder A, Martinez-Soria N, Fordham SE, Shi Y, Russell LJ, Pal D, Smith A, Kingsbury Z, Becq J, Eckert C, Haas OA, Carey P, Bailey S, Skinner R, Miakova N, Collin M, Bigley V, Haniffa M, Marschalek R, Harrison CJ, Cargo CA, Schewe D, Olshanskaya Y, Thirman MJ, Cockerill PN, Mulloy JC, Blair HJ, Vormoor J, Allan JM, Bonifer C, Heidenreich O, Bomken S. Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia. Blood 2022, 140(17), 1875-1890.
- Marin-Rubio JL, Peltier-Heap RE, Duenas ME, Heunis T, Dannoura A, Inns J, Scott J, Simpson AJ, Blair HJ, Heidenreich O, Allan JM, Watt JE, Martin MP, Saxty B, Trost M. A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia. Journal of Medicinal Chemistry 2022, 65(18), 12014-12030.
- Wilson A, Hockney S, Parker J, Angel S, Blair H, Pal D. A human mesenchymal spheroid prototype to replace moderate severity animal procedures in leukaemia drug testing. F1000Research 2022, 11, 1280.
- Shi Y, Beckett MC, Blair HJ, Tirtakusuma R, Nakjang S, Enshaei A, Halsey C, Vormoor J, Heidenreich O, Krippner-Heidenreich A, van Delft FW. Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia. Haematologica 2021, 106(4), 1056-1066.
- Forde S, Matthews JD, Jahangiri L, Lee LC, Prokoph N, Malcolm TIM, Giger OT, Bell N, Blair H, O'Marcaigh A, Smith O, Kenner L, Bomken S, Burke GAA, Turner SD. Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy. British Journal of Haematology 2021, 192(2), 354-365.
- Fidyt K, Pastorczak A, Goral A, Szczygiel K, Fendler W, Muchowicz A, Bartlomiejczyk MA, Madzio J, Cyran J, Graczyk-Jarzynka A, Jansen E, Patkowska E, Lech-Maranda E, Pal D, Blair H, Burdzinska A, Pedzisz P, Glodkowska-Mrowka E, Demkow U, Gawle-Krawczyk K, Matysiak M, Winiarska M, Juszczynski P, Mlynarski W, Heidenreich O, Golab J, Firczuk M. Targeting the thioredoxin system as a novel strategy against B-cell acute lymphoblastic leukemia. Molecular Oncology 2019, 13(5), 1180-1195.
- Assi SA, Imperato MR, Coleman DJL, Pickin A, Potluri S, Ptasinska A, Chin PS, Blair H, Cauchy P, James SR, Zacarias-Cabeza J, Gilding LN, Beggs A, Clokie S, Loke JC, Jenkin P, Uddin A, Delwel R, Richards SJ, Raghavan M, Griffiths MJ, Heidenreich O, Cockerill PN, Bonifer C. Subtype-specific regulatory network rewiring in acute myeloid leukemia. Nature Genetics 2019, 51(1), 151-162.
- Potter N, Jones L, Blair H, Strehl S, Harrison CJ, Greaves M, Kearney L, Russell LJ. Single cell analysis identifies CRLF2 rearrangements as both early and late events in Down syndrome and non-Down syndrome acute lymphoblastic leukaemia. Leukemia 2019, 33, 893-904.
- Matheson EC, Thomas H, Case M, Blair H, Jackson RK, Masic D, Veal G, Halsey C, Newell DR, Vormoor J, Irving JAE. Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM. Haematologica 2019, 104(9), 1804-1811.
- Martinez-Soria N, McKenzie L, Draper J, Ptasinska A, Issa H, Potluri S, Blair HJ, Pickin A, Isa A, Chin PS, Tirtakusuma R, Coleman D, Nakjang S, Assi S, Forster V, Reza M, Law E, Berry P, Mueller D, Elder A, Bomken SN, Pal D, Allan JM, Veal GJ, Cockerill PN, Wichmann C, Vormoor J, Lacaud G, Bonifer C, Heidenreich O. The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation. Cancer Cell 2018, 34(4), 626-642.e8.
- Fordham SE, Blair HJ, Elstob CJ, Plummer R, Drew Y, Curtin NJ, Heidenreich O, Pal D, Jamieson D, Park C, Pollard J, Fields S, Milne P, Jackson GH, Marr HJ, Menne T, Jones GJ, Allan JM. Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase. Blood Advances 2018, 2(10), 1157-1169.
- Sinclair PB, Blair HH, Ryan SL, Buechler L, Cheng J, Clayton J, Hanna R, Hollern S, Hawking Z, Bashton M, Schwab CJ, Jones L, Russell LJ, Marr H, Carey P, Halsey C, Heidenreich O, Moorman AV, Harrison CJ. Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Haematologica 2018, 103, 634-644.
- Vormoor B, Schlosser YT, Blair H, Sharma A, Wilkinson S, Newell DR, Curtin N. Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2. Oncotarget 2017, 8(69), 113418-113430.
- Noble RA, Bell N, Blair H, Sikka A, Thomas H, Phillips N, Nakjang S, Miwa S, Crossland R, Rand V, Televantou D, Long A, Keun HC, Bacon CM, Bomken S, Critchlow SE, Wedge SR. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and burkitt lymphoma. Haematologica 2017, 102(7), 1247-1257.
- McCormick A, Earp E, Elliot K, Cuthbert G, O'Donnell R, Wilson BT, Sutton R, Leeson C, Thomas HD, Blair H, Fordham S, Lunec J, Allan J, Edmondson RJ. Functional characterisation of a novel ovarian cancer cell line, NUOC-1. Oncotarget 2017, 8(16), 26832-26844.
- Elder A, Bomken S, Wilson I, Blair HJ, Cockell S, Ponthan F, Dormon K, Pal D, Heidenreich O, Vormoor J. Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia. Leukemia 2017, 31, 2577-2586.
- Williams MT, Yousafzai YM, Elder A, Rehe K, Bomken S, Frishman-Levy L, Tavor S, Sinclair P, Dormon K, Masic D, Perry T, Weston VJ, Kearns P, Blair H, Russell LJ, Heidenreich O, Irving JA, Izraeli S, Vormoor J, Graham GJ, Halsey C. The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts. Blood 2016, 127(16), 1998-2006.
- Pal D, Blair HJ, Elder A, Dormon K, Rennie KJ, Coleman DJL, Weiland J, Rankin KS, Filby A, Heidenreich O, Vormoor J. Long-term in vitro maintenance of clonal abundance and leukaemia-initiating potential in acute lymphoblastic leukaemia. Leukemia 2016, 30, 1691-1700.
- Irving J, Matheson E, Minto L, Blair H, Case M, Halsey C, Swidenbank I, Ponthan F, Kirschner-Schwabe R, Groeneveld-Krentz S, Hof J, Allan J, Harrison C, Vormoor J, von Stackelberg A, Eckert C. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood 2014, 124(23), 3420-3430.
- Scherr M, Elder A, Battmer K, Barzan D, Bomken S, Ricke-Hoch M, Schröder A, Venturini L, Blair HJ, Vormoor J, Ottmann O, Ganser A, Pich A, Hilfiker-Kleiner D, Heidenreich O, Eder M. Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. Leukemia 2014, 28, 554-565.
- Vormoor B, Knizia HK, Batey MA, Almeida GS, Wilson I, Dildey P, Sharma A, Blair H, Hide IG, Heidenreich O, Vormoor J, Maxwell RJ, Bacon CM. Development of a Preclinical Orthotopic Xenograft Model of Ewing Sarcoma and Other Human Malignant Bone Disease Using Advanced In Vivo Imaging. PLoS ONE 2014, 9(1), e85128.
- Bomken S, Buechler L, Rehe K, Ponthan F, Elder A, Blair H, Bacon CM, Vormoor J, Heidenreich O. Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression. Leukemia 2013, 27(3), 718-721.
- Nakatomi M, Hovorakova M, Gritli-Linde A, Blair HJ, Macarthur K, Peterka M, Lesot H, Peterkova R, Ruiz-Perez VL, Goodship JA, Peters H. Evc regulates a symmetrical response to Shh signaling in molar development. Journal of Dental Research 2013, 92(3), 222-228.
- Blair HJ, Tompson S, Liu YN, Campbell J, MacArthur K, Ponting CP, Ruiz-Perez VL, Goodship JA. Evc2 is a positive modulator of Hedgehog signalling that interacts with Evc at the cilia membrane and is also found in the nucleus. BMC Biology 2011, 9(1), 14.
- Tompson SWJ, Ruiz-Perez VL, Blair HJ, Barton S, Navarro V, Robson JL, Wright MJ, Goodship JA. Sequencing EVC and EVC2 identifies mutations in two-thirds of Ellis-van Creveld syndrome patients. Human Genetics 2007, 120(5), 663-670.
- Ruiz-Perez VL, Blair HJ, Rodrigues-Andres ME, Blanco MJ, Wilson A, Liu Y-N, Miles C, Peters H, Goodship JA. Evc is a positive mediator of Ihh-regulated bone growth that localises at the base of chondrocyte cilia. Development 2007, 134(16), 2903-2912.
- Garcia CC, Blair HJ, Seager M, Coulthard A, Tennant S, Buddles M, Curtis A, Goodship JA. Identification of a mutation in synapsin I, a synaptic vesicle protein, in a family with epilepsy. Journal of Medical Genetics 2004, 41(3), 183-186.
- Ruiz-Perez VL, Tompson SWJ, Blair HJ, Espinoza-Valdez C, Lapunzina P, Silva EO, Hamel B, Gibbs JL, Young ID, Wright MJ, Goodship JA. Mutations in two nonhomologous genes in a head-to-head configuration cause Ellis-van Creveld syndrome. American Journal of Human Genetics 2003, 72(3), 728-732.
- Ann Clark M, Blair H, Liang L, Brey RN, Brayden D, Hirst BH. Targeting polymerised liposome vaccine carriers to intestinal M cells. Vaccine 2001, 20(1-2), 208-217.
- Blair HJ, Reed V, Gormally E, Wilson JB, Novak J, McInnes RR, Phillips SJ, Taylor BA, Boyd Y. Positioning of five genes (CASK, ARX, SAT, IMAGE cDNAs 248928 and 253949 from the human X chromosome short arm with respect to evolutionary breakpoints on the mouse X chromosome. Mammalian Genome 2000, 11(8), 710-712.
- Blair HJ, Gormally E, Uwechue IC, Boyd Y. Mouse mutants carrying deletions that remove the genes mutated in Coffin-Lowry syndrome and lactic acidosis. Hum Mol Genet 7 7 549-555 1998.
- Boyd Y, Blair HJ, Cunliffe P, Denny P, Gormally E, Herman GE. Encylopedia of the mouse genome VII. Mouse chromosome X. Mamm Genome 8 8 S361-377 1998.
- Blair HJ, Uwechue IC, Barsh GS, Rowe PS, Boyd Y. An integrated genetic and man-mouse comparative map of the DXHXS674-Pdha1 region of the mouse X chromosome. Genomics 48 48 128-31 1998.
- Laval SH, Reed V, Blair HJ, Boyd Y. The structure of DXF34, a human X-linked sequence family with homology to a transcribed mouse Y-linked repeat. Mamm Genome 8 8 689-691 1997.
- Boyd Y, Herman GE, Avner P, Disteche CM, Adler D, Reed V, Blair HJ. Mouse X chromosome. Mamm Genome 7 7 S313-326 1997.
- Uwechue IC, Cooper BF, Goble C, Hacker T, Blair HJ, Burke DT, Herman G, Boyd Y. The mouse X-linked developmental mutant, tattered, lies between DXMit55 and Xkh and is associated with hyperkeratinization. Genomics 37 37 238-241 1996.
- Laval SH, Blair HJ, Mitchell MJ, Boyd Y. Smcx lies distal to DXHX674 and DXHX679 on the mouse X chromosome. Mamm Genome 7 7 552 1996.
- Herman GE, Blair HJ, Boyd SD, De Gouyon B, Haynes A, Quaderi N. Encyclopedia of the mouse genome V. Mouse X chromosome. Mamm Genome 6 6 C317-330 1996.
- Blair HJ, Ho M, Monaco AP, Fisher S, Craig IW, Boyd Y. High-resolution comparative mapping of the proximal region of the mouse X chromosome. Genomics 28 28 305-310 1995.
- Blair HJ, Reed V, Laval SH, Boyd Y. New insignts into the man-mouse comparative map of the X-chromosome. Genomics 19 19 212-220 1994.
- Blair HJ, Hirst MC, MacKinnon R, Davies KE, Boyd Y. Evaluation of human microdissection clones from the FRAXA region as tools for comparative mapping in the mouse: isolation of a conserved genomic clone close to FMR1. Mamm Genome 5 5 584-587 1994.
- Reed V, Rider S, Maslen GL, Hatchwell E, Blair HJ, Uwechue IC, Craig IW, Laval SH, Monaco AP, Boyd Y. A 2-Mb YAC contig encompassing three loci (DXF34, DXS14 and DXS390) that lie between Xp11.2 translocation breakpoints associated with incontinentia pigmenti type 1. Genomics 20 20 341-346 1994.
- Blair HJ, Reed V, Laval SH, Boyd Y. The locus for pyruvate dehydrogenase E1 alpha subunit (Pdha1) lies between Plp and Amg on the mouse X chromosome. Mamm Genome 4 4 230-233 1993.
- Laval SH, Blair HJ, Hirst MC, Davies KE, Boyd Y. Mapping of FMR1, the gene implicated in fragile X-linked mental retardation, on the mouse X chromosome. Genomics 12 12 818-821 1992.
-
Conference Proceedings (inc. Abstracts)
- McKenzie L, Martinez-Soria N, Draper J, Nakjang S, Blair HJ, Wichmann C, Vormoor J, Bonifer C, Lacaud G, Heidenreich O. Identification of CCND2 As a RUNX1/ETO Target Required for Leukaemic Propagation. In: 58th ASH Annual Meeting. 2016, San Diego, CA, USA: American Society of Hematology.
- Bell N, Blair H, Noble R, Price L, Wood K, Vormoor J, Bacon C, Rand V, Heidenreich O, Wedge S, Bomken S. Patient-derived xenograft and in vivo bioluminescent modelling of B-cell NHL. In: Fifth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma. 2015, Varese, Italy: Wiley-Blackwell.
- Vormoor B, Schlosser Y, Blair H, Wilkinson S, Newell DR, Curtin N. Inhibition of DNA-Repair Enzymes (DNA-Pk and Parp) to Sensitize Ewing Sarcoma to Chemo-And Radiotherapy. In: 47th Congress of the International Society of Paediatric Oncology (SIOP). 2015, Cape Town, South Africa: Wiley-Blackwell.
- Elder A, Blair H, Dormon K, Bomken S, Cockell SJ, Heidenreich O, Vormoor J. High Abundance of Acute Lymphoblastic Leukaemia Founder Clones Does Not Translate to Functional Heterogeneity. In: 57th ASH Annual Meeting. 2015, Orlando, USA: American Society of Hematology.
- Dormon K, Latif ES, Bashton M, Pal D, Selby M, Blair H, Rand V, Hall AG, Vormoor J, Heidenreich O. A Whole Genome In Vivo Crispr Screen in Primary ALL Predicts Leukaemic Relapse. In: ASH 2015 Annual Meeting. 2015, Orlando, USA: American Society of Hematology.
- Sinclair P, Cheng J, Raninga P, Hanna R, Hollern S, Enshaei A, Blair H, Nakjang S, Ryan S, Eswaran J, Buechler L, Heidenreich O, Harrison C. A Targeted Functional Clone Tracking Assay for the Identification of Tumour Suppressor Genes in BCP- ALL Implicates the Transcription Factors FOXO3 and PRDM1. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA: American Society of Hematology.
- Batey MA, Ponthan F, Blair HJ, Heidenreich O. The development and evaluation of a series of novel in vivo imaging models of AML for the assessment of drug efficacy. In: AACR Annual Meeting 2014. 2014, San Diego, CA: American Association for Cancer Research.
- Bomken S, Elder A, Blair H, Scherr M, Eder M, Vormoor J, Heidenreich O. Preclinical modelling of childhood acute lymphoblastic leukaemia. In: Spring Meeting for Clinician Scientists in Training. 2014, Royal College of Physicians, London: The Lancet Publishing Group.
- Bell N, Blair HJ, Vormoor J, Bacon C, Rand V, Heidenreich O, Bomken S. Development of in Vivo Models of Paediatric Burkitt Lymphoma Allowing Therapeutic Target Analysis and Drug Testing. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, CA: American Society of Hematology.
- Bomken S, Buechler L, Rehe K, Ponthan F, Blair H, Heidenreich O, Vormoor J. Lentiviral Transduction of Patient Derived Leukaemic Blasts Allowing In Vivo Bioluminescent Monitoring in An NSG Model of Leukaemia Stem Cell Maintenance. In: Blood: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH). 2011, San Diego, California, USA: American Society of Hematology.
- Blair HJ, Tompson S, Liu YN, Campbell J, Goodship JA. Evc and Evc2 are interacting cilia transmembrane proteins that modulate Ihh signalling. In: Mechanisms of Development: 16th Annual Conference of the International Society of Development Biologists. 2009, Edinburgh, UK: Elsevier Ireland Ltd.
- Goodship J, Blair H, Wilson A, Liu YN, Rodriguez-Andres M, Blanco M, Peters H, Miles C, Ruiz-Perez V. Evc is a positive mediator of Ihh signalling. In: JOURNAL OF MEDICAL GENETICS. 2007, BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND: B M J PUBLISHING GROUP.
- Goodship J, Garcia CC, Blair HJ, Seager M, Coulthard A, Tennent S, Buddles M, Curtis A. Deficiency of synapsin I, a synaptic vesicle protein, causes epilepsy. In: Journal of Medical Genetics: British Human Genetics Conference. 2003, York, UK: BMJ Group.
-
Online Publication
- Singh M, Blair H, Berry P, Heidenreich O. Multi-drug chemotherapy dose optimisation in preclinical leukaemia models using HPLC-MS/MS. Thieme, 2020. Available at: https://doi.org/10.1055/s-0040-1709781.
-
Review
- Boyd Y, Blair HJ, Cunliffe P, Masson WK, Reed V. A phenotype map of the mouse X chromosome: Models for human X-linked disease. Genome Research 2000, 10(3), 277-292.